☰

Claire Colas - Publications

Affiliations: 
2011-2013 ICSN CNRS, Paris, Île-de-France, France 
Tree Info Similar researchers PubMed Report error

32/44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Colas C. Toward a Systematic Structural and Functional Annotation of Solute Carriers Transporters-Example of the SLC6 and SLC7 Families. Frontiers in Pharmacology. 11: 1229. PMID 32973497 DOI: 10.3389/Fphar.2020.01229  0.4
2020 Colas C, Banci G, Martini R, Ecker GF. Studies of structural determinants of substrate binding in the Creatine Transporter (CreaT, SLC6A8) using molecular models. Scientific Reports. 10: 6241. PMID 32277128 DOI: 10.1038/S41598-020-63189-Z  0.428
2020 Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gürtl B, Klavins K, Klimek C, Lindinger S, Liñeiro-Retes E, Müller AC, Onstein S, Redinger G, ... ... Colas C, et al. The RESOLUTE consortium: unlocking SLC transporters for drug discovery. Nature Reviews. Drug Discovery. PMID 32265506 DOI: 10.1038/D41573-020-00056-6  0.325
2020 Troger F, Delp J, Funke M, van der Stel W, Colas C, Leist M, van de Water B, Ecker GF. Identification of mitochondrial toxicants by combined in silico and in vitro studies – A structure-based view on the adverse outcome pathway Computational Toxicology. 14: 100123. DOI: 10.1016/J.Comtox.2020.100123  0.341
2020 Banci G, Martini R, Colas C, Franz Ecker G. A Novel Structural Model of the Creatine Transporter Rationalizes its Structural Determinants of Binding Biophysical Journal. 118: 443a. DOI: 10.1016/J.Bpj.2019.11.2480  0.4
2019 Hall C, Wolfe H, Wells A, Chien HC, Colas C, Schlessinger A, Giacomini KM, Thomas AA. l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan. Bioorganic & Medicinal Chemistry Letters. PMID 31248771 DOI: 10.1016/J.Bmcl.2019.06.033  0.362
2019 Viktoria G, Colas C, Ecker GF. Structural Determinants of the hASBT-Ligands Interactions Biophysical Journal. 116: 552a. DOI: 10.1016/J.Bpj.2018.11.2971  0.322
2018 Garibsingh RA, Otte NJ, Ndaru E, Colas C, Grewer C, Holst J, Schlessinger A. Homology Modeling Informs Ligand Discovery for the Glutamine Transporter ASCT2. Frontiers in Chemistry. 6: 279. PMID 30137742 DOI: 10.3389/Fchem.2018.00279  0.468
2018 Chien HC, Colas C, Finke K, Springer S, Stoner L, Zur AA, Venteicher B, Campbell J, Hall C, Flint A, Augustyn E, Hernandez C, Heeren N, Hansen L, Anthony A, et al. Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). Journal of Medicinal Chemistry. PMID 30048132 DOI: 10.1021/Acs.Jmedchem.8B01007  0.419
2018 Ilgü H, Jeckelmann JM, Colas C, Ucurum Z, Schlessinger A, Fotiadis D. Effects of Mutations and Ligands on the Thermostability of the l-Arginine/Agmatine Antiporter AdiC and Deduced Insights into Ligand-Binding of Human l-Type Amino Acid Transporters. International Journal of Molecular Sciences. 19. PMID 29558430 DOI: 10.3390/Ijms19030918  0.382
2018 Colas C, Masuda M, Sugio K, Miyauchi S, Hu Y, Smith DE, Schlessinger A. Structure-Based Ligand Discovery for the Human Oligopeptide Transporter 1, PEPT1 Biophysical Journal. 114: 330a. DOI: 10.1016/J.Bpj.2017.11.1849  0.379
2017 Colas C, Masuda M, Sugio K, Miyauchi S, Hu Y, Smith DE, Schlessinger A. Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1. Molecular Pharmaceutics. PMID 29111754 DOI: 10.1021/Acs.Molpharmaceut.7B00775  0.434
2017 Colas C, Schlessinger A, Pajor AM. Mapping functionally important residues in the Na+/dicarboxylate cotransporter, NaDC1. Biochemistry. PMID 28731330 DOI: 10.1021/Acs.Biochem.7B00503  0.375
2017 Colas C, Schlessinger A. Homology Modeling and Ligand Optimization for the Human Amino Acid Exchanger Lat-1 (SLC7A5) Biophysical Journal. 112: 337a. DOI: 10.1016/J.Bpj.2016.11.1823  0.43
2016 Singh K, Tanui R, Gameiro A, Eisenberg G, Colas C, Schlessinger A, Grewer C. Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2. Bioorganic & Medicinal Chemistry Letters. PMID 28057420 DOI: 10.1016/J.Bmcl.2016.12.063  0.469
2016 Colas C, Ung PM, Schlessinger A. SLC Transporters: Structure, Function, and Drug Discovery. Medchemcomm. 7: 1069-1081. PMID 27672436 DOI: 10.1039/C6Md00005C  0.42
2016 Zur AA, Chien HC, Augustyn E, Flint A, Heeren N, Finke K, Hernandez C, Hansen L, Miller S, Lin L, Giacomini KM, Colas C, Schlessinger A, Thomas AA. LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates. Bioorganic & Medicinal Chemistry Letters. PMID 27624080 DOI: 10.1016/J.Bmcl.2016.09.001  0.377
2016 Klotz J, Porter BE, Colas C, Schlessinger A, Pajor AM. Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay. Molecular Medicine (Cambridge, Mass.). 22. PMID 27261973 DOI: 10.2119/Molmed.2016.00077  0.319
2016 Augustyn E, Finke K, Zur AA, Hansen L, Heeren N, Chien HC, Lin L, Giacomini KM, Colas C, Schlessinger A, Thomas AA. LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs. Bioorganic & Medicinal Chemistry Letters. PMID 27106710 DOI: 10.1016/J.Bmcl.2016.04.023  0.426
2016 Colas C, Pajor AM, Schlessinger A. Structural Characterization of Substrate Transport Selectivity of the SLC13 Family of Na+/Dicarboxylate Cotransporters Biophysical Journal. 110: 627a. DOI: 10.1016/J.Bpj.2015.11.3362  0.457
2015 Colas C, Grewer C, Otte NJ, Gameiro A, Albers T, Singh K, Shere H, Bonomi M, Holst J, Schlessinger A. Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening. Plos Computational Biology. 11: e1004477. PMID 26444490 DOI: 10.1371/Journal.Pcbi.1004477  0.471
2015 Colas C, Pajor AM, Schlessinger A. Structure-Based Identification of Inhibitors for the SLC13 Family of Na(+)/Dicarboxylate Cotransporters. Biochemistry. 54: 4900-8. PMID 26176240 DOI: 10.1021/Acs.Biochem.5B00388  0.437
2014 Desrat S, Pujals A, Colas C, Dardenne J, Gény C, Favre L, Dumontet V, Iorga BI, Litaudon M, Raphaël M, Wiels J, Roussi F. Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1. Bioorganic & Medicinal Chemistry Letters. 24: 5086-8. PMID 25266781 DOI: 10.1016/J.Bmcl.2014.09.004  0.546
2014 Schlessinger A, Sun NN, Colas C, Pajor AM. Determinants of substrate and cation transport in the human Na+/dicarboxylate cotransporter NaDC3. The Journal of Biological Chemistry. 289: 16998-7008. PMID 24808185 DOI: 10.1074/Jbc.M114.554790  0.42
2014 Colas C, Iorga BI. Virtual screening of the SAMPL4 blinded HIV integrase inhibitors dataset. Journal of Computer-Aided Molecular Design. 28: 455-62. PMID 24458507 DOI: 10.1007/S10822-014-9707-5  0.532
2014 Desrat S, Remeur C, Gény C, Rivière G, Colas C, Dumontet V, Birlirakis N, Iorga BI, Roussi F. From meiogynin A to the synthesis of dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins Chemical Communications. 50: 8593. DOI: 10.1039/C4Cc01830C  0.527
2014 Nicolas C, Porceddu M, Buron N, Wang Z, Colas C, Iorga B, Ambroise Y, Vandecasteele G, Fischmeister R, Borgne-Sanchez A, Brenner C. 0256: A screening strategy to identify modulators of the mitochondrial ADP/ATP translocase (ANT) for cardioprotection Archives of Cardiovascular Diseases Supplements. 6: 58. DOI: 10.1016/S1878-6480(14)71422-3  0.498
2014 Colas C, Schlessinger A. Description of the Structural Determinants of the hPepT1-Ligand Interactions Biophysical Journal. 106: 149a. DOI: 10.1016/J.Bpj.2013.11.860  0.404
2013 Prevost MS, Delarue-Cochin S, Marteaux J, Colas C, Van Renterghem C, Blondel A, Malliavin T, Corringer PJ, Joseph D. Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC. Journal of Medicinal Chemistry. 56: 4619-30. PMID 23682762 DOI: 10.1021/Jm400374Q  0.369
2012 Colas C, Brotel X, Duclert-Savatier N, Nilges M, Joseph D, Malliavin TE. Lobeline docking on AChBP and nicotinic receptors: Discriminating importance of the pocket geometry and of the ligand configuration Letters in Drug Design and Discovery. 9: 54-62. DOI: 10.2174/157018012798193017  0.345
2012 Dardenne J, Pujals A, Colas C, Birlirakis N, Wiels J, Dumontet V, Geny C, Iorga B, Guéritte F, Roussi F. Pharmacomodulation of Meiogynin A, a dimeric sesquiterpenoid inhibiting BCL-XL and BAK interaction Planta Medica. 78. DOI: 10.1055/S-0032-1320396  0.519
2011 Taly A, Colas C, Malliavin T, Blondel A, Nilges M, Corringer PJ, Joseph D. Discrimination of agonists versus antagonists of nicotinic ligands based on docking onto AChBP structures. Journal of Molecular Graphics & Modelling. 30: 100-9. PMID 21764343 DOI: 10.1016/J.Jmgm.2011.06.008  0.354
Low-probability matches (unlikely to be authored by this person)
2023 Dvorak V, Casiraghi A, Colas C, Koren A, Tomek T, Offensperger F, Rukavina A, Tin G, Hahn E, Dobner S, Frommelt F, Boeszoermenyi A, Bernada V, Hannich JT, Ecker GF, et al. Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors. Cell Chemical Biology. 30: 953-964.e9. PMID 37516113 DOI: 10.1016/j.chembiol.2023.06.029  0.287
2021 Colas C, Laine E. Targeting Solute Carrier Transporters through Functional Mapping. Trends in Pharmacological Sciences. 42: 3-6. PMID 33234336 DOI: 10.1016/j.tips.2020.11.005  0.285
2016 Colas C, Smith DE, Schlessinger A. Computing Substrate Selectivity in a Peptide Transporter. Cell Chemical Biology. 23: 211-3. PMID 26971872 DOI: 10.1016/J.Chembiol.2016.02.001  0.285
2021 Niello M, Cintulová D, Raithmayr P, Holy M, Jäntsch K, Colas C, Ecker GF, Sitte HH, Mihovilovic MD. Effects of Hydroxylated Mephedrone Metabolites on Monoamine Transporter Activity . Frontiers in Pharmacology. 12: 654061. PMID 33897439 DOI: 10.3389/fphar.2021.654061  0.269
2020 Cosco J, Scalise M, Colas C, Galluccio M, Martini R, Rovella F, Mazza T, Ecker GF, Indiveri C. ATP modulates SLC7A5 (LAT1) synergistically with cholesterol. Scientific Reports. 10: 16738. PMID 33028978 DOI: 10.1038/s41598-020-73757-y  0.264
2023 Schlessinger A, Zatorski N, Hutchinson K, Colas C. Targeting SLC transporters: small molecules as modulators and therapeutic opportunities. Trends in Biochemical Sciences. PMID 37355450 DOI: 10.1016/j.tibs.2023.05.011  0.248
2022 Colas C, Bahar I, Shi L, Font Sadurni J. Editorial: Targeting Membrane Proteins: Structure-Function-Dynamics Relationships. Frontiers in Chemistry. 10: 862802. PMID 35308796 DOI: 10.3389/fchem.2022.862802  0.135
2024 Baudot A, Barth N, Colas C, Garros M, Garcin A, Oriol M, Collange F, Bongue B, Roche F, Chauvin F, Bourmaud A, Hupin D. The Acti-Pair program helps men with prostate cancer increase physical activity with peer support: a mixed method pilot study. Frontiers in Public Health. 11: 1321230. PMID 38259748 DOI: 10.3389/fpubh.2023.1321230  0.06
2021 Colas C, Jumel A, Vericel MP, Barth N, Manzanares J, Goutte J, Fontana L, Féasson L, Hupin D, Guyot J. Understanding Experiences of Fibromyalgia Patients Involved in the Fimouv Study During COVID-19 Lockdown. Frontiers in Psychology. 12: 645092. PMID 34354626 DOI: 10.3389/fpsyg.2021.645092  0.057
2021 Colas C, Goutte J, Creac'h C, Fontana L, Vericel MP, Manzanares J, Peuriere M, Akrour M, Martin C, Presles E, Barth N, Guyot J, Garros M, Trombert B, Massoubre C, et al. Efficiency of an Optimized Care Organization in Fibromyalgia Patients: The From Intent to Move (FIMOUV) Study Protocol of a Randomized Controlled Trial. Frontiers in Public Health. 9: 554291. PMID 34113593 DOI: 10.3389/fpubh.2021.554291  0.056
2023 Colas C, Le Berre Y, Fanget M, Savall A, Killian M, Goujon I, Labeix P, Bayle M, Féasson L, Roche F, Hupin D. Physical Activity in Long COVID: A Comparative Study of Exercise Rehabilitation Benefits in Patients with Long COVID, Coronary Artery Disease and Fibromyalgia. International Journal of Environmental Research and Public Health. 20. PMID 37569053 DOI: 10.3390/ijerph20156513  0.023
2022 Colas C, Bayle M, Labeix P, Botelho-Nevers E, Gagneux-Brunon A, Cazorla C, Schein F, Breugnon E, Garcin A, Feasson L, Roche F, Hupin D. Management of Long COVID-The CoviMouv' Pilot Study: Importance of Adapted Physical Activity for Prolonged Symptoms Following SARS-CoV2 Infection. Frontiers in Sports and Active Living. 4: 877188. PMID 35847457 DOI: 10.3389/fspor.2022.877188  0.013
Hide low-probability matches.